Mainz Biomed N.V. (NASDAQ:MYNZ) does about 2.01M shares in volume on a normal day but saw 2305153 shares change hands in the recent trading day. The company now has a market cap of 5.67M USD. Its current market price is $0.26, marking a decrease of -6.87% compared to the previous close of $0.28. The 52 week high reached by this stock is $3.39 whilst the lowest price level in 52 weeks is $0.19.
Mainz Biomed N.V. (MYNZ) has a 20-day trading average at $0.2897 and the current price is -92.37% off the 52-week high compared with 39.85% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.3055 and its 200-day simple moving average is $0.6494. If we look at the stock’s price movements over the week, volatility stands at 12.70%, which increases to 16.63% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 43.79 to suggest the stock is neutral.
The consensus objective for the share price is $4.00, suggesting that the stock has a potential upside of 93.5% over the period.
The current price level is -10.60%, -15.21%, and -60.12% away from its SMA20, SMA50, and SMA200 respectively, with the MYNZ price moving above the 50-day SMA on current market day. Mainz Biomed N.V. (MYNZ) stock is down -14.55% over the week and 21.08% over the past month. Its price is -77.67% year-to-date and -87.49% over the past year.
The stock last released its quarterly earnings report for quarter ended 12/31/2023, with the company’s earnings per share (EPS) of -0.56 below consensus estimates by -0.14. The company’s next earnings report forecasts estimating quarterly EPS at -0.25 and -0.87 for whole year. Expected sales for next quarter are $300k, which analysts say will come at $1.2M for the current fiscal year and next year at $2.3M. In addition, estimates put the company’s current quarterly revenue at an average of $220k.
To reach the target analysts have set, the stock logically needs to grow 93.5 percent from here.
The company has a return on investment of -595.61%. The beta has a value of 0.09. Price to book ratio is 1.69 and price to sales ratio is 6.30.
